TrialsgrambetaRCTs are beautiful

2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults

This guideline cites 4 of the 199 landmark trials in our Cardiology register.

This is a de novo American guideline — the first ACC/AHA document devoted to acute pulmonary embolism — and its central act is nomenclature: it retires 'massive/submassive' and introduces the AHA/ACC Acute Pulmonary Embolism Clinical Categories, a severity scheme that sits alongside, but does not map one-to-one onto, the ESC 2019 high/intermediate-high/intermediate-low/low-risk stratification. Direct oral anticoagulants remain the default, full-dose systemic fibrinolysis remains reserved for haemodynamic collapse, and catheter-directed therapy is given a more permissive, PE-response-team-mediated role than in the European document, while both acknowledge that the randomised evidence for it is still thin. The register's anticoagulation, reperfusion and reversal trials are grouped below.

Anticoagulation: direct oral anticoagulants1

  • 2013HOKUSAI-VTE⁠Cardiology · Thrombosis · Venous thromboembolismIn 8,240 patients with acute venous thromboembolism after initial heparin, once-daily edoxaban was non-inferior for recurrent symptomatic venous thromboembolism and caused less clinically relevant bleeding than warfarin.HR 0.8995% CI 0.70-1.13Read →

Cancer-associated venous thromboembolism1

  • 2020CARAVAGGIO⁠Cardiology · Thrombosis · Venous thromboembolismIn 1,170 patients with cancer-associated venous thromboembolism, apixaban was non-inferior to dalteparin for recurrent VTE, without excess major bleeding.HR 0.63Read →

Reperfusion: systemic & catheter-directed2

  • 2014PEITHO Core⁠Cardiology · Thrombosis · Pulmonary embolismIn 1,006 patients with intermediate-risk pulmonary embolism, tenecteplase reduced haemodynamic decompensation but increased major and intracranial bleeding compared with heparin alone.OR 0.44Read →
  • 2014ULTIMA⁠Cardiology · Thrombosis · Pulmonary embolismIn 59 patients with intermediate-risk pulmonary embolism and right-ventricular dilatation, ultrasound-assisted catheter-directed thrombolysis reversed the right-ventricular-to-left-ventricular diameter ratio at 24 hours more than unfractionated heparin alone.Read →

Cited landmark trials not yet in the register5

Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.

  • 2006PIOPED II

    CT pulmonary angiography accuracy — the basis of the diagnostic algorithm.

  • 2017EINSTEIN-CHOICE

    Reduced-dose rivaroxaban versus aspirin for extended VTE prevention.

  • 2018Hokusai VTE Cancer

    Edoxaban versus dalteparin in cancer-associated thrombosis.

  • 2024PEERLESS

    Large-bore mechanical thrombectomy versus catheter-directed thrombolysis in intermediate-risk PE.

  • 2022HI-PEITHO

    Ultrasound-facilitated catheter-directed thrombolysis in intermediate-high-risk PE — the trial both guidelines are waiting for.

Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.